PARENCHIMA will boost the use of renal MRI biomarkers to improve the management of chronic kidney disease patients
The rising prevalence of Chronic Kidney Disease (CKD) poses a major public health challenge affecting >10% of the population. But the field has not seen a truly new therapy in over 15 years, and an alarming number of large recent CKD progression trials have failed. In order to overcome this challenge, there is an urgent need for better biomarkers to identify patients that are at risk of progression, or are likely to respond to candidate therapeutics. Magnetic Resonance Imaging (MRI) biomarkers have shown a high potential to help fill this gap as they are non-invasive and sensitive to CKD pathophysiology.